On the eve of the Olympics' opening ceremony in Rio de Janeiro, there's good news on combating the Zika virus: a promising vaccine effective in monkeys and now being fast-tracked for human clinical trials.
A purified, inactivated Zika virus vaccine earlier found to work in mice is effective against Brazilian and Puerto Rican strains of the virus in monkeys, too, researchers from the Walter Reed Army Institute of Research and Harvard Medical School reported in a study out on Thursday in the journal Science.
Phase 1 clinical testing of the vaccine, developed by the Walter Reed Institute, is expected to start in October.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
